Extract
Tuberculosis (TB) caused by strains of Mycobacterium tuberculosis that are rifampicin-resistant (RR), multidrug-resistant (MDR) (strains resistant to at least isoniazid and rifampicin) or extensively drug-resistant (XDR) (MDR strains resistant to any fluoroquinolone (FQ) and to at least one second-line injectable drug (SLID): kanamycin, capreomycin or amikacin) is a major threat to TB control globally. All three groups require treatment with second-line drugs (SLDs) [1]. We previously reported that MDR- and XDR-TB in Italy occurred mostly in foreign-born persons (FBPs) [2, 3], but no major information on RR, MDR or XDR trends in FBPs and Italian-born persons (IBPs) were shown. Here, we documented these trends from 2009 to 2016 (figure 1).
Abstract
In Italy, rifampicin-resistant and MDR-TB were high in foreign-born persons, but decreased from 2009 to 2016 http://ow.ly/MrIy30jNjFj
Acknowledgements
The members of the SMIRA laboratory network are: V. Ghisetti and A. Mondo (Hospital Savoia, Turin); M. Avolio and A. Barbui (Hospital Molinette, Turin); P. Lorenzetti (Hospital of Aosta, Aosta); G. De Renzi and M.G. Chirillo (Hospital of Orbassano, Orbassano); G. Molinari, A. Camaggi and S. Andreoni (Hospital of Novara, Novara); F. Piana (Hospital of Cuneo, Cuneo); A. Marchese, P. Gritti, G. Icardi and O. Varnier (Hospital San Martino, Genoa); E. Mazzola and G. Gesu (Hospital Niguarda, Milan); P. Cichero (Hospital San Raffaele, Milan); A. Lombardi (Hospital Sacco, Milan); E. Libanori, P. Viggiani and S. De Lorenzo (Hospital of Sondalo, Sondalo); G. Pinsi (Spedali Civili, Brescia); P. Marone, V. Monzillo and D. Barbarini (Hospital San Matteo, Pavia); C. Farina and M. Arosio (Hospital Giovanni XXIII, Bergamo); M. Peracchi and R. Manganelli (Hospital of Padova, Padua); C. Fabris, M. Di Santolo and M. Busetti (Hospital of Trieste, Trieste); C. Scarparo and A. Sartor (Hospital of Udine, Udine); C. Pedrotti and I. Caola (Hospital of Trento, Trent); E. Frizzera (Hospital of Bolzano, Bolzano); P. Dal Monte (Hospital San Orsola-Malpighi, Bologna); P. Pietrosemoli, M. Pecorari, A. Fabio and A. la Regina (Hospital of Modena, Modena); M. Matteucci (Area Vasta Romagna, Pievesestina, Cesena); C. Piersimoni (Hospital of Ancona, Ancona); A. Bartolesi, R. Mannino, T. Simonetti and E. Tortoli (Hospital Careggi, Florence); L. Rindi (University of Pisa, Pisa); A. Mencacci, E. Cenci, E. Luciano and R. Mazzolla, (Hospital of Perugia, Perugia); I. Sanguigni, G. Parisi, P. Chiaradonna and A.M. Altieri (H. San Camillo-Forlanini, Rome); S. D'Arezzo, A. Mazzarelli, A. Di Caro and E. Bordi (Hospital Spallanzani, Rome); M. Sali, G. Delogu and M. Sanguinetti (Hospital Gemelli, Rome); C. Russo, L. Coltella and A. Ciocco (Hospital Bambino Gesù, Rome); M. Meledandri (Hospital San Filippo Neri, Rome); A. Gambi and G. Tomei (Hospital of Chieti, Chieti); M. Conte, G. Santoro and A. del Giudice (Hospital dei Colli, Naples); N. Nuzzolese, E. Vitullo, A. Sinno and L. Buono (Hospital of Matera, Matera); D. Costa (Hospital of Bari, Bari); A. Grimaldi (Hospital of Triggiano, Bari); A. Di Taranto and R. De Nittis (Hospital of Foggia, Foggia); G. Palumbo (Hospital of Lecce, Lecce); S. Dodaro, C. Giraldi and P. Cavalcanti (Hospital of Cosenza, Cosenza); S. Nisticò and L. Vinci (Hospital of Lamezia Terme, Lamezia Terme); C. Di Naso (Hospital Garibaldi Centro, Catania); C. Bonura, C.M. Maida and C. Mammina (Hospital Giaccone of Palermo, Palermo); and G.S. Podda and R. Caddeu (Hospital of Cagliari, Cagliari).
Footnotes
Support statement: This study was supported by the CCM Project of the Ministry of Health, in the framework of the DPCM 03.03.2017 (GU 109, 12.05.2017) on the Surveillance systems and Registry of mortality, cancer and other pathologies. Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: None declared.
- Received January 12, 2018.
- Accepted April 24, 2018.
- Copyright ©ERS 2018
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
